ArticleScientific reports2020
Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: a nanovaccine confer immuneadjuvanting effects to fight cervical cancer.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Common predictors of cervical cancer related mortality in Ethiopia. A systematic review and meta-analysis.BMC public health · 2024Pooled it
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Leveraging Microorganisms to Combat Skin Cancer.Microorganisms · 2025Review
- Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.Cancer chemotherapy and pharmacology · 2025Review
- Sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant.Human vaccines & immunotherapeutics · 2024Review
- Current status and future directions for the development of human papillomavirus vaccines.Frontiers in immunology · 2024Review
- Review
- Review
- Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems.Pathogens (Basel, Switzerland) · 2022Review
- Plasmid DNA for Therapeutic Applications in Cancer.Pharmaceutics · 2022Review
- Vesicular and Planar Membranes of Archaea Lipids: Unusual Physical Properties and Biomedical Applications.International journal of molecular sciences · 2022Review
- New Perspectives in Therapeutic Vaccines for HPV: A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.Frontiers in pharmacology · 2022Review
- Review
- Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.Cancers · 2021Review
- Archaeosomes and Gas Vesicles as Tools for Vaccine Development.Frontiers in immunology · 2021Review
- Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.Frontiers in immunology · 2021Review
- Oncoimmunology Meets Organs-on-Chip.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a leading cause of death worldwide. Cervical cancer caused by human papillomavirus (HPV) is a major health problem in women. DNA vaccines are a perfect approach to immunization, but their potency in clinical trials has been insufficient for generating effective immunity, which may be related to the degradation of the DNA via nucleases, poor delivery to antigen-presenting cells (APCs), and insufficient uptake of DNA plasmids by cells upon injection. Archaeosome is a nano-delivery systems based on liposomes with their immunological role have been developed for gene delivery. In this study, human papillomavirus type 16 genes, containing truncated L1, E6, and E7, were simultaneously used in combination therapy with archaeosome and assessed in vivo. Findings supported that archaeosomes promotes immune responses to DNA vaccines and a long-term CTL response was generated with a low antigen dose. Combination therapy with archaeosome/L1/E6/E7 vaccines exhibited a strong cytolytic activity against tumor cells and induced prophylactic and therapeutic effect against the development of tumor in the animal model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.